- Home
- EQ vs LSTA Comparison
EQ vs LSTA Comparison
Compare EQ & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- LSTA
- Stock Information
- Founded
- EQ 2017
- LSTA 1980
- Country
- EQ United States
- LSTA United States
- Employees
- EQ N/A
- LSTA N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- EQ Health Care
- LSTA Health Care
- Exchange
- EQ Nasdaq
- LSTA Nasdaq
- Market Cap
- EQ 24.8M
- LSTA 24.2M
- IPO Year
- EQ 2018
- LSTA N/A
- Fundamental
- Price
- EQ $0.59
- LSTA $2.71
- Analyst Decision
- EQ Buy
- LSTA Strong Buy
- Analyst Count
- EQ 2
- LSTA 1
- Target Price
- EQ $5.00
- LSTA $15.00
- AVG Volume (30 Days)
- EQ 117.7K
- LSTA 18.6K
- Earning Date
- EQ 11-13-2024
- LSTA 11-12-2024
- Dividend Yield
- EQ N/A
- LSTA N/A
- EPS Growth
- EQ N/A
- LSTA N/A
- EPS
- EQ N/A
- LSTA N/A
- Revenue
- EQ $45,914,000.00
- LSTA N/A
- Revenue This Year
- EQ $4.76
- LSTA N/A
- Revenue Next Year
- EQ N/A
- LSTA N/A
- P/E Ratio
- EQ N/A
- LSTA N/A
- Revenue Growth
- EQ 7.70
- LSTA N/A
- 52 Week Low
- EQ $0.56
- LSTA $2.19
- 52 Week High
- EQ $3.25
- LSTA $3.83
- Technical
- Relative Strength Index (RSI)
- EQ 33.48
- LSTA 49.17
- Support Level
- EQ $0.56
- LSTA $2.52
- Resistance Level
- EQ $0.67
- LSTA $2.75
- Average True Range (ATR)
- EQ 0.05
- LSTA 0.19
- MACD
- EQ -0.00
- LSTA -0.00
- Stochastic Oscillator
- EQ 15.79
- LSTA 75.36
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.